FibroBiologics, Inc. Common Stock (FBLG) Stock
Key stats
- Market cap
- $7.05M
- Price / Earnings ratio
- -0.3x
- EPS (TTM)
- -$5.19
- Volume
- Loading
- 52-week high
- $3.97
- 52-week low
- $0.19
Source: third-party data provider, as of November 13, 2026
Compare with FBLG
Technical indicators
- RSI 14
- 47.31
- MACD 12/26/9
- -0.05
- EMA 9 of MACD
- -0.07
- MACD histogram
- 0.02
- SMA 50
- $1.21
- Price below SMA 50
- EMA 50
- $1.10
- Price below EMA 50
- SMA 200
- $2.14
- Price below SMA 200
- EMA 200
- $2.49
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
About FibroBiologics, Inc. Common Stock
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Peter O'Heeron | Founder, Chairperson & CEO | 1964 |
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer | 1970 |
| Mr. Ruben A. Garcia J.D. | General Counsel | 1977 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 47.31
- MACD 12/26/9
- -0.05
- EMA 9 of MACD
- -0.07
- MACD histogram
- 0.02
- SMA 50
- $1.21
- Price below SMA 50
- EMA 50
- $1.10
- Price below EMA 50
- SMA 200
- $2.14
- Price below SMA 200
- EMA 200
- $2.49
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -74.4 | -0.8 | -20.5 | -15.2 | -23.1 | +117.7 | -38.4 | -23.1 | +8.7 |
Corporate actions
Upcoming
No upcoming corporate actions for FBLG




